Brief: Carsgen Therapeutics Says Introduction Of Zhuhai Sb Xinchuang In China
26/02/2025 15:41
Feb 26 (Reuters) - CARsgen Therapeutics 2171.HK: INTRODUCTION OF ZHUHAI SB XINCHUANG TO ACCELERATE ALLOGENEIC CAR-T CELL PRODUCTS DEVELOPMENT IN MAINLAND CHINA INVESTMENT FUND TO SUBSCRIBE FOR ADDITIONAL REGISTERED CAPITAL OF UCARSGEN BIOTECH FOR RMB80 MILLION Further company coverage: 2171.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on CARsgen Therapeutics Holdings
See all newsBrief: Carsgen Therapeutics Says CT1190B Receives IND Clearance From NMPA For Relapsed/Refractory Large B-Cell Lymphoma
Brief: Carsgen Therapeutics Says CT0596 Receives IND Clearance From NMPA
Brief: Carsgen Therapeutics Approves Share Repurchase Plan For Up To 30.12 Million Shares
CARsgen Therapeutics climbs on board nod for share buyback
Brief: Carsgen Therapeutics Says NMPA Approves Satricabtagene Autoleucel For Advanced Gastric Cancer